A Phase I Study of Famitinib Malate in Patients With Solid Tumor

Inclusion Criteria: * Histological confirmed advanced or metastatic solid tumor，at least one measurable lesion, larger than 10 mm in diameter by spiral CT scan(scanning layer ≤ 5 mm ) * no standard therapy protocol available according to patients'condition * both sex, age 18 to 65 * ECOG 0-1 * Life expectancy more than 3 months * ALT,AST,TB≤1.5(UNL),normal serum creatinine level, normal electrolyte or can be corrected by medication * Subjects receiving damage caused by other therapeutic has been restored, the interval more than six weeks since the last receiving nitroso or mitomycin; more than 4 weeks since last receiving radiotherapy, other cytotoxic drugs or surgery * Understand and agree to sign informed consent form. Exclusion Criteria: * Peripheral neuropathy ≥ Grade 2(according to NCI-CTC 3.0) * Preexisting uncontrolled hypertension defined as more than 140/90 mmHg by using single agent therapy, \>Grade 1 (NCI-CTCAE 3.0 ) myocardial ischemia, arrhythmia,cardiac function insufficiency * PT, APTT, TT, Fbg abnormal(PT\>16s,APTT\>43s,TT\>21s,Fbg\<2g/L), or have hemorrhagic tendency or receiving the therapy of thrombolysis or anticoagulation * Active peptic ulcer * Previously medication include sunitinib * More than 4 weeks since the last clinical trial * Pregnant or lactating women * Women of childbearing age do not take effective contraceptive measures * Allergies, or known allergy history to components of the drug